A detailed history of Morgan Stanley transactions in 89bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 400,238 shares of ETNB stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400,238
Previous 292,445 36.86%
Holding current value
$2.75 Million
Previous $2.34 Million 26.43%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $793,356 - $1.04 Million
107,793 Added 36.86%
400,238 $2.96 Million
Q2 2024

Oct 17, 2024

SELL
$7.31 - $10.9 $3.8 Million - $5.67 Million
-520,177 Reduced 64.01%
292,445 $2.34 Million
Q2 2024

Aug 14, 2024

SELL
$7.31 - $10.9 $3.8 Million - $5.67 Million
-520,177 Reduced 64.01%
292,445 $2.34 Million
Q1 2024

Oct 17, 2024

BUY
$8.13 - $13.77 $4.23 Million - $7.16 Million
520,177 Added 177.87%
812,622 $9.46 Million
Q1 2024

Aug 16, 2024

SELL
$8.13 - $13.77 $5.5 Million - $9.32 Million
-676,638 Reduced 45.43%
812,622 $9.46 Million
Q1 2024

May 15, 2024

SELL
$8.13 - $13.77 $5.5 Million - $9.32 Million
-676,638 Reduced 45.43%
812,622 $9.46 Million
Q4 2023

Aug 16, 2024

BUY
$6.66 - $16.03 $7.97 Million - $19.2 Million
1,196,815 Added 409.24%
1,489,260 $16.6 Million
Q4 2023

Feb 13, 2024

BUY
$6.66 - $16.03 $5.92 Million - $14.3 Million
889,506 Added 148.31%
1,489,260 $16.6 Million
Q3 2023

Nov 15, 2023

SELL
$15.06 - $19.41 $15.8 Million - $20.3 Million
-1,047,262 Reduced 63.59%
599,754 $9.26 Million
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $483,604 - $752,919
34,177 Added 2.12%
1,647,016 $31.2 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $15.8 Million - $25.5 Million
1,507,728 Added 1434.42%
1,612,839 $24.6 Million
Q4 2022

Feb 14, 2023

SELL
$5.52 - $12.73 $150,442 - $346,943
-27,254 Reduced 20.59%
105,111 $1.34 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $102,698 - $238,042
34,006 Added 34.57%
132,365 $767,000
Q2 2022

Oct 27, 2022

BUY
$2.09 - $4.02 $58,624 - $112,760
28,050 Added 39.9%
98,359 $317,000
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $58,624 - $112,760
28,050 Added 39.9%
98,359 $317,000
Q1 2022

Oct 27, 2022

SELL
$3.45 - $14.99 $96,772 - $420,469
-28,050 Reduced 28.52%
70,309 $264,000
Q1 2022

May 13, 2022

BUY
$3.45 - $14.99 $108,167 - $469,981
31,353 Added 80.48%
70,309 $264,000
Q4 2021

Feb 14, 2022

SELL
$11.15 - $19.66 $1.96 Million - $3.45 Million
-175,428 Reduced 81.83%
38,956 $509,000
Q3 2021

Nov 15, 2021

BUY
$14.91 - $21.31 $3.2 Million - $4.57 Million
214,384 New
214,384 $4.2 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $320M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.